Defence Therapeutics Inc. Expands into U.S. with New Laboratory in Boston-Cambridge Biotech Hub
Defence Therapeutics Inc., a Canadian biotechnology company listed on the Canadian National Stock Exchange, has announced the opening of its first U.S. laboratory in the Boston-Cambridge biotech hub. This strategic move marks the company’s initial physical presence in the United States and underscores its commitment to advancing research and development in one of the world’s leading biotech clusters.
The new laboratory, situated at Cambridge Scientific Labs in Watertown, is set to enhance Defence Therapeutics’ capabilities in developing and optimizing its proprietary Accum® technology for antibody-drug conjugates (ADCs). This technology is central to the company’s mission of creating innovative therapies for diseases such as cancer and immune system-related conditions.
By establishing a presence in the Boston-Cambridge area, Defence Therapeutics gains access to top-tier scientific resources and opportunities for collaboration within the region’s renowned biotech ecosystem. This positioning is expected to foster valuable industry partnerships and drive further advancements in their research initiatives.
While the current laboratory space at Cambridge Scientific Labs serves as a short-term base, Defence Therapeutics is evaluating options for a long-term facility. This transition may involve additional costs and potential disruptions, but it reflects the company’s strategic vision for sustained growth and innovation in the U.S. market.
As of May 29, 2025, Defence Therapeutics’ stock closed at CAD 0.76, with a market capitalization of CAD 46,520,000. The company’s 52-week high was CAD 1.66, and its low was CAD 0.48. Despite a negative price-to-earnings ratio of -9.43, the expansion into the U.S. is a significant step in the company’s efforts to transform patient outcomes through novel, targeted treatments.